IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,82 -0,85 (-1,02%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
58.862,31 +593,98 (+1,02%)
Oramed Pharmaceuticals Inc. (ORMP)
Después del cierre:
Oramed Pharmaceuticals Inc.
1185 Avenue of the Americas
3rd Floor
New York, NY 10036
United States
844 967 2633
https://www.oramed.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Nadav Kidron Esq. | President, CEO & Executive Chairman | 754,3k | N/A | 1974 |
| Mr. David Silberman CPA | CFO & Treasurer | 259,53k | N/A | 1984 |
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer & Director | 503,95k | N/A | 1940 |
| Mr. Joshua Hexter | Chief Operating & Business Officer | 326,94k | N/A | 1970 |
Descripción
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Gobierno corporativo
El ISS Governance QualityScore de Oramed Pharmaceuticals Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
